|
[1] BOSMAN FT,CARNEIRO F,HRUBAN RH,et al. WHO classification of tumours of the digestive system[M]. Lyon:IARC Press,2010:1089.
|
|
[2] YAO JC,HASSAN M,PHAN A,et al. One hundred years after“carcinoid”:Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J]. J Clin Oncol,2008,26(18):3063-3072.
|
|
[3] HAO ZQ,LI WX,LI Q,et al. Gallbladder neuroendocrine carcinoma:A report of 3 cases and literature review[J]. J Clin Hepatol,2018,34(2):400-402.(in Chinese)郝志强，李文心，李强，等．胆囊神经内分泌癌3例诊治分析并文献复习[J]．临床肝胆病杂志，2018,34(2):400-402.
|
|
[4] MAITRA A,TASCILAR M,HRUBAN RH,et al. Small cell carcinoma of the gallbladder:A clinicopathologic,immunohistochemical,and molecular pathology study of 12 cases[J]. Am J Surg Pathol,2001,25(5):595-601.
|
|
[5] STELOW EB,HONG SM,FRIERSON JHF. Gallbladder and extrahepatic biliary system[M]//Mills SE. Histology for Pathologists,3rd ed. Philadelphia:Lippincott Williams&Wilkins,2007:705-722.
|
|
[6] SHINTAKU M,KATAOKA K,KAWABATA K. Mixed adenoneuroendocrine carcinoma of the gallbladder with squamous cell carcinomatous and osteosarcomatous differentiation:Report of a case[J]. Pathol Int,2013,63(2):113-119.
|
|
[7] IWASA S,MORIZANE C,OKUSAKA T,et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas[J]. Jpn J Clin Oncol,2010,40:313-318.
|
|
[8] OBERG KE,REUBI JC,KWEKKEBOOM DJ,et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy[J]. Gastroenterology,2010,139(3):742-753.
|
DownLoad: